With a growing understanding of AML splicing dysregulation, new therapeutic targets may gradually emerge, and therapeutic strategies that target key spliceosome elements (such as SF3B1) or specific oncogenic splice variants in a manner that circumvents resistance mechanisms may prove invaluable in eradicating these types of AML clones [27]. This evidence concerns the gene SF3B1 and acute myeloid leukemia.